US FDA extends review of Pfizer's Fablyn until January
This article was originally published in Scrip
The US FDAhas extended the review period for Pfizer's selective oestrogen receptor modulator (SERM), Fablyn (lasofoxifene), by three months until January to analyse complete five-year data from the pivotal PEARL study, the company said. In September an advisory panel endorsed approval of Fablyn for the treatment of osteoporosis in women. Committee members generally recommended the SERM for second-line use owing to safety issues raised during clinical trials, including increases in all-cause mortality, thromboembolic events and gynaecological problems. At the time of the meeting preliminary five-year data from the 8,556-patient, placebo-controlled PEARL study were available, but a final report had not been submitted to the agency. The FDA concluded that three-year PEARL data demonstrated lasofoxifene was effective in significantly reducing the risk of new or worsening radiographic vertebral fractures.
You may also be interested in...
Heading into an advisory committee review, agency suggests belantamab’s risks of keratopathy and other ocular issues have not been fully characterized and questions whether the proposed mitigation measures, including dosing modifications, are adequate.
US FDA cardiovascular and renal drugs panel will weigh approvability of the vasopressin analog during a nine-hour, online meeting 15 July; terlipressin was the focus of a 2009 complete response letter but met its primary endpoint in the recent CONFIRM trial.
Under certain circumstances, potential clinical trial participants may be able to provide informed consent by writing on a blank piece of paper that they voluntarily agree to participate in a given protocol, and texting or emailing a photo of the signed document to the investigator, the US FDA says in its latest guidance update.